Last reviewed · How we verify
TCA 20%
At a glance
| Generic name | TCA 20% |
|---|---|
| Also known as | Trichloroacetic acid |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Discontination of Antidepressants in Remitted Depression (PHASE4)
- A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (PHASE2)
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
- Hemadsorption to Enhance Drug Elimination in Intoxications (NA)
- PDT vs Peels for Treatment of Actinic Keratoses (PHASE2)
- Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform (PHASE4)
- Recrudescence of Eating Conduct Disorders and Covid-19
- Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCA 20% CI brief — competitive landscape report
- TCA 20% updates RSS · CI watch RSS
- Cairo University portfolio CI